Drug intelligence / Profile preview

PTH-0300

Development stage: Unknown
Lead developer: Protheragen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

PTH-0300 is a monoclonal antibody developed by Protheragen that targets interleukin-25 (IL-25). IL-25, also known as IL-17E, is a pro-inflammatory cytokine that plays a critical role in the initiation and maintenance of Type 2 immune responses, which are associated with allergic diseases and chronic inflammation. By neutralizing IL-25, PTH-0300 aims to inhibit the downstream production of Type 2 cytokines such as IL-4, IL-5, and IL-13, thereby providing a therapeutic approach for Type 2 inflammatory diseases. The drug is currently in Phase I clinical development.

Targets

IL25 (IL-25)

Beyond the preview

Go deeper on PTH-0300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTH-0300.

Explore the full profile